Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Atlas Intermediate LLC

Neither a doctor nor a teaching hospital

Research payments

$988,059

107 payments

Through program year 2025, Atlas Intermediate LLC is reported as receiving $988,059 in research payments, across 107 payments.

By program year

2 rows
Year Kind Amount Payments
2025 Research $783,995 91
2024 Research $204,064 16

Breakdown

Who paid Research payments · program years 2024–2025
  1. AbbVie, Inc. $578,878 67 payments
  2. Moderna TX, Inc. $318,360 25 payments
  3. Merz Pharmaceuticals, LLC $36,300 6 payments
  4. Pfizer Inc. $27,403 6 payments
  5. Janssen Research & Development, LLC $27,118 3 payments
Studies the money was for Research payments · program years 2024–2025
  1. A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants $429,998 41 payments
  2. A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants $318,360 25 payments
  3. Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder $58,216 7 payments
  4. M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants $31,813 4 payments
  5. A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants $30,890 2 payments
  6. An Interventional Efficacy and Safety Phase 3 Doubleblind Parallel Group Study to Investigate Intermittent Prevention of Menstrual Migraine With Rimegepant Compared With Placebo in Women Participants 18 to 45 Years of Age $27,403 6 payments
  7. A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety ofJNJ-77242113 for the Treatment of Biologic-experienced Participants with Active Psoriatic Arthritis $27,118 3 payments
  8. A Clinical Trial to Evaluate Efficacy and Safety of Xeomin Injections for Preventing Episodic Migraine $18,150 3 payments
  9. A Clinical Trial to Evaluate Efficacy and Safety of Xeomin Injections for Preventing Chronic Migraine $18,150 3 payments
  10. A Phase 2/3 Multicenter, Double Blinded, Randomized, Dose-conversion, Active Control Study Examining the Efficacy and Safety of Armour Thyroid Compared to Synthetic T4 for the Treatment of Adults With Primary Hypothyroidism $11,867 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record